Brain Tumor Treatment in India
India's leading neurosurgery and neuro-oncology centres treat gliomas, meningiomas, pituitary adenomas, and brain metastases with advanced techniques including awake craniotomy, intraoperative MRI, Gamma Knife radiosurgery, and proton therapy.
Get a Free Treatment Plan in 48 Hours
Send your reports — our specialists will review and send a personalised treatment plan and cost estimate.
📋 Get Free ConsultationSigns & Symptoms of Brain Tumors
- Persistent headaches (often worse in the morning)
- Seizures (new onset)
- Vision, speech, or hearing problems
- Weakness or numbness in limbs
- Memory problems or personality changes
- Balance and coordination difficulties
Treatment Options Available in India
- Craniotomy with awake brain mapping
- Minimally invasive / endoscopic surgery
- Gamma Knife / CyberKnife stereotactic radiosurgery
- Intensity-modulated radiotherapy (IMRT)
- Proton beam therapy
- Temozolomide chemotherapy (for glioblastoma)
- Bevacizumab for recurrent glioma
Why Treat Brain Tumors in India?
India offers world-class cancer care at a fraction of Western costs, with no compromise on quality or outcomes.
| Cost Comparison | India | USA |
|---|---|---|
| Brain Tumors Treatment (total) | $6,000–$20,000 | $50,000–$250,000 |
| Savings with India | 60–80% less than USA | |
Best Hospitals
- AIIMS, New Delhi (Neurosciences Centre)
- Apollo Hospitals, Chennai & Delhi
- Fortis Memorial Research Institute, Gurugram
- Manipal Hospital, Bangalore
- NIMHANS, Bangalore
Key Facts
- India has 50+ advanced neurosurgery centres
- Gamma Knife radiosurgery costs $6,000–$10,000 in India vs $40,000–$80,000 in USA
- Intraoperative MRI available at AIIMS, Apollo, Fortis
- IDH mutation, MGMT methylation, 1p/19q co-deletion testing available in 5–7 days
Frequently Asked Questions
Q: Is brain tumor surgery safe in India?
A: Yes. Top neurosurgeons in India have trained at Harvard, Johns Hopkins, and leading European centres. Craniotomy-related mortality at top Indian centres is under 1% for benign tumours and 2–3% for complex malignant cases.